Article Information
History
- April 29, 2020.
Article Versions
- Version 1 (April 24, 2020 - 21:12).
- You are currently viewing Version 2 of this article (April 29, 2020 - 14:06).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Veronique Michaud, Chief Operating Officer, BPharm, PhD1,
- Pamela Dow, Clinical Research Manager, MS1,
- Sweilem B. Al Rihani, Clinical Research Scientist, PharmD, PhD1,
- Malavika Deodhar, Clinical Research Scientist, BPharm, PhD1,
- Meghan Arwood, Clinical Research Scientist, PharmD1,
- Brian Cicali, PhD Student, Pharmaceutics, MSc2 and
- Jacques Turgeon, Chief Scientific Officer, BPharm, PhD1,*
- 1Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, 13485 Veteran’s Way, Suite 410, Orlando, Florida, 32827, USA
- 2University of Florida Center for Pharmacometrics and Systems Pharmacology, 6550 Sanger Road, Orlando, FL 32827
- ↵*Correspondence to: Jacques Turgeon, B.Pharm., Ph.D., Chief Scientific Officer, Tabula Rasa HealthCare, 13485 Veteran’s Way, Suite 410, Orlando, Florida, 32827, USA; email: jturgeon{at}trhc.com
Posted April 29, 2020.
Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: A systematic review
